Literature DB >> 14733756

Potential impact of population-based colorectal cancer screening in Canada.

William M Flanagan1, Christel Le Petit, Jean-Marie Berthelot, Kathleen J White, B Ann Coombs, Elaine Jones-McLean.   

Abstract

Randomized controlled trials (RCT) have shown the efficacy of screening for colorectal cancer (CRC) using the faecal occult blood test (FOBT) with follow-up by colonoscopy. We evaluated the potential impact of population-based screening by FOBT followed by colonoscopy in Canada: mortality reduction, cost-effectiveness, and resource requirements. The microsimulation model POHEM was adapted to simulate CRC screening using Canadian data and RCT results about test sensitivity and specificity, participation, incidence, staging, progression, mortality and direct health care costs. In Canada, biennial screening of 67% of individuals aged 50-74 in the year 2000 resulted in an estimated 10-year CRC mortality reduction of 16.7%. The life expectancy of the cohort increased by 15 days on average and the demand for colonoscopy rose by 15% in the first year. The estimated cost of screening was $112 million per year or $11,907 per life-year gained (discounted at 5%). Potential effectiveness would depend on reaching target participation rates and finding resources to meet the demand for FOBT and colonoscopy. This work was conducted in support of the National Committee on Colorectal Cancer Screening.

Entities:  

Mesh:

Year:  2003        PMID: 14733756

Source DB:  PubMed          Journal:  Chronic Dis Can        ISSN: 0228-8699


  20 in total

Review 1.  Simulation models of obesity: a review of the literature and implications for research and policy.

Authors:  D T Levy; P L Mabry; Y C Wang; S Gortmaker; T T-K Huang; T Marsh; M Moodie; B Swinburn
Journal:  Obes Rev       Date:  2010-10-26       Impact factor: 9.213

Review 2.  Who provides gastrointestinal endoscopy in Canada?

Authors:  R J Hilsden; J Tepper; P Moayyedi; L Rabeneck
Journal:  Can J Gastroenterol       Date:  2007-12       Impact factor: 3.522

Review 3.  CT colonography and cost-effectiveness.

Authors:  Ifigeneia Mavranezouli; James E East; Stuart A Taylor
Journal:  Eur Radiol       Date:  2008-06-27       Impact factor: 5.315

Review 4.  The value of models in informing resource allocation in colorectal cancer screening: the case of The Netherlands.

Authors:  Frank van Hees; Ann G Zauber; Harriët van Veldhuizen; Marie-Louise A Heijnen; Corine Penning; Harry J de Koning; Marjolein van Ballegooijen; Iris Lansdorp-Vogelaar
Journal:  Gut       Date:  2015-06-10       Impact factor: 23.059

5.  Cost-effectiveness of colorectal cancer screening - an overview.

Authors:  Iris Lansdorp-Vogelaar; Amy B Knudsen; Hermann Brenner
Journal:  Best Pract Res Clin Gastroenterol       Date:  2010-08       Impact factor: 3.043

Review 6.  Reducing the costs of chronic kidney disease while delivering quality health care: a call to action.

Authors:  Raymond Vanholder; Lieven Annemans; Edwina Brown; Ron Gansevoort; Judith J Gout-Zwart; Norbert Lameire; Rachael L Morton; Rainer Oberbauer; Maarten J Postma; Marcello Tonelli; Wim Van Biesen; Carmine Zoccali
Journal:  Nat Rev Nephrol       Date:  2017-05-30       Impact factor: 28.314

7.  Resource implications for a population-based colorectal cancer screening program in Canada: a study of the impact on colonoscopy capacity and costs in London, Ontario.

Authors:  Agatha Lau; James C Gregor
Journal:  Can J Gastroenterol       Date:  2007-06       Impact factor: 3.522

8.  Overview of methods to estimate the medical costs of cancer.

Authors:  William E Barlow
Journal:  Med Care       Date:  2009-07       Impact factor: 2.983

9.  Trends in colorectal cancer admissions and stage at presentation: impact of screening.

Authors:  Zhobin Moghadamyeghaneh; Reza Fazl Alizadeh; Michael Phelan; Joseph C Carmichael; Steven Mills; Alessio Pigazzi; Jason A Zell; Michael J Stamos
Journal:  Surg Endosc       Date:  2015-11-05       Impact factor: 4.584

10.  Prevalence of screening in patients newly diagnosed with colorectal cancer in Ontario.

Authors:  C Taylor; S E Schultz; L F Paszat; S Bondy; L Rabeneck
Journal:  Can J Gastroenterol       Date:  2007-12       Impact factor: 3.522

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.